Research programme: somatropin controlled release - Avadel Pharmaceuticals
Alternative Names: hGH XLLatest Information Update: 04 Nov 2017
At a glance
- Originator Flamel Technologies
- Developer Avadel Pharmaceuticals
- Class Growth hormones
- Mechanism of Action Somatotropin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Growth disorders
Highest Development Phases
- No development reported Growth disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Growth-disorders in Europe (SC, Controlled release)
- 03 Jan 2017 Flamel Technologies completed its cross-border merger with Avadel Pharmaceuticals and is now called Avadel Pharmaceuticals
- 29 Jan 2004 Preclinical trials in Growth disorders in Europe (Injection)